Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage

Clinical Cancer Research

Volumn 8, Issue 8, 2002, Pages 2735-2741

  Nabha, Sanaa M ^a   Mohammad, Ramzi M ^a   Dandashi, Mahmoud H ^a   Coupaye Gerard, Brigitte ^b   Aboukameel, Amro ^a   Pettit, George R ^c   Al Katib, Ayad M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BENZYLOXYCARBONYLLEUCYLMETHOXYGLUTAMYLHISTIDYLMETHOXYASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BIOLOGICAL MARKER; CASPASE; CASPASE 3; CASPASE 9; CASPASE 9 INHIBITOR; CASPASE INHIBITOR; COMBRETASTATIN A4; CYCLIN B1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MITOTIC PROTEIN MONOCLONAL 2 ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLANT EXTRACT; PRODRUG; PROTEIN 14 3 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN CDC2; PROTEIN CDC25; PROTEIN KINASE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN WEE1; REGULATOR PROTEIN; ROTEIN CHK1; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CHECKPOINT KINASE 1; COMBRETASTATIN A 4; COMBRETASTATIN A-4; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; EXONUCLEASE; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; SFN PROTEIN, HUMAN; STILBENE DERIVATIVE; TUMOR PROTEIN;

ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DEATH; CELL DENSITY; CHRONIC LYMPHATIC LEUKEMIA; COMBRETUM CAFFRUM; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME BINDING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MITOSIS; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; PHYTOTHERAPY; PLANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; CELL CULTURE; CELL CYCLE G2 PHASE; CELL NUCLEUS; CELL SURVIVAL; FLOW CYTOMETRY; GENETIC MARKER; METABOLISM; PHOSPHORYLATION; TIME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CASPASES; CELL NUCLEUS; CELL SURVIVAL; CYCLINS; ENZYME ACTIVATION; ENZYME INHIBITORS; EXONUCLEASES; FLOW CYTOMETRY; G2 PHASE; GENETIC MARKERS; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MITOSIS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PRODRUGS; PROTEIN KINASES; PROTEIN P34CDC2; PROTEIN P53; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; STILBENES; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TUMOR CELLS, CULTURED; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 9; CDC2 PROTEIN KINASE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036023440     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines
2. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4
3. The interaction with tubulin of a series of stilbenes based on combretastatin A-4
4. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
5. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
6. Cancer statistics, 2000
7. 2 delay causes HeLa cells to undergo apoptosis instead of mitotic death
8. Biochemical differences between staurosporine-induced apoptosis and premature mitosis
9. Delayed DNA damage associated with mitotic catastrophe following X-irradiation of Hela S3 cells
10. Caspase-dependent apoptosis induced by telomere cleavage and TRF2 loss
11. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage
12. 2 DNA damage checkpoint system
13. Mdm2 expression is induced by wild type p53 activity
14. Caspases: Enemies within
15. Death receptors: Signaling and modulation
16. Establishment of a human B-CLL xenograft model: Utility as a preclinical therapeutic model
17. Checkpoint on the nuclear frontier
18. Monoclonal antibodies to mitotic cells
19. 2-phase DNA content
20. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members
21. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: A novel target mechanism concept for pharmacokinetic modulating chemotherapy
22. Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation
23. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival